The recent discovery of ADAMTS13 conformation as a potential contributor to TTP in addition to the proposal of using the absolute immature platelet count (A-IPC) as a biomarker, present novel areas for monitoring and treatment. This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.